Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
LEO Pharma said on September 26 that it has launched Adtralza (tralokinumab) in Japan for the treatment of atopic dermatitis inadequately controlled with existing therapies. The drug had obtained approval in December last year. Adtralza is an anti-IL-13 antibody that…
To read the full story
Related Article
- LEO Pharma’s Adtralza Pen Version Now Available in Japan
December 3, 2024
- LEO Pharma Wins Approval for Pen Version of Adtralza
August 6, 2024
- LEO Pharma’s Eczema Drug Adtralza OK’ed for Self-Injection
March 14, 2024
- Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023
- LEO Pharma Files Tralokinumab for Atopic Dermatitis in Japan
January 31, 2022
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…